HCA Healthcare (HCA) Stock Forecast & Price Target

$330.10 +8.36 (+2.60%)

Closing price 03/7/2025 03:59 PM Eastern

Extended Trading

$326.10 -4.01 (-1.21%)

As of 03/7/2025 07:46 PM Eastern

HCA Healthcare - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 18 Analyst Ratings

Sell
1

Hold
3

Buy
14

Based on 18 Wall Street analysts who have issued ratings for HCA Healthcare in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 18 analysts, 1 has given a sell rating, 3 have given a hold rating, 12 have given a buy rating, and 2 have given a strong buy rating for HCA.

Consensus Price Target

$385.67
16.83% Upside

According to the 18 analysts' twelve-month price targets for HCA Healthcare, the average price target is $385.67. The highest price target for HCA is $440.00, while the lowest price target for HCA is $320.00. The average price target represents a forecasted upside of 16.83% from the current price of $330.11.

Get the Latest News and Ratings for HCA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for HCA Healthcare and its competitors.

HCA Analyst Ratings Over Time

Type	Current Forecast 3/9/24 to 3/9/25	1 Month Ago 2/8/24 to 2/7/25	3 Months Ago 12/10/23 to 12/9/24	1 Year Ago 3/10/23 to 3/9/24
Strong Buy	2 Strong Buy rating(s)	2 Strong Buy rating(s)	2 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	12 Buy rating(s)	12 Buy rating(s)	11 Buy rating(s)	10 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	5 Hold rating(s)	4 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$385.67	$385.67	$380.29	$308.26
Forecasted Upside	16.83% Upside	19.79% Upside	19.42% Upside	-5.26% Downside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Remove Ads

HCA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

HCA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

HCA Healthcare Stock vs. The Competition

Type	HCA Healthcare	Medical Companies	S&P 500
Consensus Rating Score	2.83	2.82	2.53
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	16.83% Upside	32,850.58% Upside	16.54% Upside
News Sentiment Rating	Positive News See Recent HCA News	Positive News	Positive News

Remove Ads

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
1/27/2025	Bank of America 3 of 5 stars	Kevin Fischbeck Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$380.00 ➝ $370.00	+12.36%
1/27/2025	Royal Bank of Canada 4 of 5 stars	Ben Hendrix Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$405.00 ➝ $384.00	+16.61%
1/27/2025	Cantor Fitzgerald 4 of 5 stars	Sarah James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$405.00 ➝ $405.00	+29.60%
1/27/2025	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Andrew Mok Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$392.00 ➝ $366.00	+17.12%
1/7/2025	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Gillmor Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$420.00 ➝ $370.00	+20.54%
1/6/2025	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$430.00 ➝ $390.00	+31.45%
12/17/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$406.00 ➝ $355.00	+15.41%
12/17/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral	$380.00	+22.74%
11/25/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Baxter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Equal Weight ➝ Underweight	$400.00 ➝ $320.00	-1.52%
11/22/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Ransom Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
Get the Latest News and Ratings for HCA and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for HCA Healthcare and its competitors with MarketBeat's FREE daily newsletter.
10/28/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$450.00 ➝ $440.00	+22.05%
10/28/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$390.00 ➝ $400.00	+10.22%
8/29/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Lake Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/14/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$405.00 ➝ $438.00	+18.74%
7/24/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$367.00 ➝ $396.00	+16.32%
6/28/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$359.00 ➝ $375.00	+14.85%
5/30/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Ha Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/30/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$396.00	+21.88%
1/4/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform	$277.00 ➝ $301.00	+9.85%
12/11/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$271.00	+5.23%
11/10/2023	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$280.00	+20.26%
10/25/2023	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$325.00 ➝ $275.00	+21.19%
10/25/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$324.00 ➝ $279.00	+22.87%
7/28/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$311.00 ➝ $316.00	+14.31%
6/28/2023	1-800-FLOWERS.COM Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
6/28/2023	VNET Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
5/10/2023	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$285.00 ➝ $310.00	+13.12%
4/24/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$325.00 ➝ $350.00	+23.24%
4/24/2023	Loop Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$285.00 ➝ $320.00	+13.79%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 10:05 AM ET.

Should I Buy HCA Healthcare Stock? HCA Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, March 2, 2025. Please send any questions or comments about these HCA Healthcare pros and cons to contact@marketbeat.com.

HCA Healthcare
Bull Case

Here are some ways that investors could benefit from investing in HCA Healthcare, Inc.:

HCA Healthcare, Inc. reported a strong earnings per share (EPS) of $6.22 for the latest quarter, surpassing analysts' expectations of $6.03, indicating robust financial performance.
The company has increased its quarterly dividend to $0.72 per share, up from $0.66, reflecting a commitment to returning value to shareholders. This translates to an annualized dividend of $2.88, providing a yield of 0.94%.
With a return on equity of 586.47%, HCA Healthcare, Inc. demonstrates exceptional efficiency in generating profits from shareholders' equity, which is a positive indicator for potential investors.
Analysts have a consensus rating of "Moderate Buy" for HCA Healthcare, Inc., with an average target price of $385.67, suggesting potential for stock price appreciation.
The current stock price is approximately $322.59, which may present a buying opportunity for investors looking to enter at a favorable valuation compared to the target price set by analysts.

HCA Healthcare
Bear Case

Investors should be bearish about investing in HCA Healthcare, Inc. for these reasons:

Wells Fargo downgraded HCA Healthcare, Inc. from an "equal weight" rating to an "underweight" rating, indicating a more cautious outlook on the stock's performance.
Several analysts have reduced their target prices for HCA Healthcare, Inc., with Barclays lowering it from $392.00 to $366.00, which may signal concerns about future growth prospects.
Insider selling activity has been noted, with a senior vice president selling 9,533 shares, which could raise concerns about the company's future performance from an insider perspective.
The company's net margin of 8.16% may be considered low compared to industry standards, suggesting potential challenges in profitability.
With a dividend payout ratio of 13.11%, while currently sustainable, any future financial strain could lead to cuts in dividends, which may deter income-focused investors.

HCA Forecast - Frequently Asked Questions

: According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for HCA Healthcare is $385.67, with a high forecast of $440.00 and a low forecast of $320.00.
: 18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for HCA Healthcare in the last twelve months. There is currently 1 sell rating, 3 hold ratings, 12 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" HCA shares.
: According to analysts, HCA Healthcare's stock has a predicted upside of 16.83% based on their 12-month stock forecasts.
: HCA Healthcare has been rated by research analysts at Bank of America, Barclays, Cantor Fitzgerald, JPMorgan Chase & Co., KeyCorp, Morgan Stanley, Royal Bank of Canada, and Truist Financial in the past 90 days.
: Analysts like HCA Healthcare more than other "medical" companies. The consensus rating score for HCA Healthcare is 2.83 while the average consensus rating score for "medical" companies is 2.82. Learn more on how HCA compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:HCA) was last updated on 3/9/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HCA Healthcare (HCA) Stock Forecast & Price Target